Faslodex™ for the treatment of breast cancer

Drugs of Today

Volumn 37, Issue 11, 2001, Pages 783-789

  Smolnikar, Kai ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOMETRIUM CARCINOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; POSTMENOPAUSE; PREMENOPAUSE; REVIEW;

EID: 0035684276     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases
2. The pharmacology and clinical uses of tamoxifen
3. Use of tamoxifen for breast cancer: Twenty-eight years later
4. Tamoxifen in advanced breast cancer
5. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
6. Should clinicians be concerned about the carcinogenic potential of tamoxifen?
7. Mechanisms of tamoxifen resistance
8. ICI 182780, a new antiestrogen with clinical potential
9. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182780
10. ICI 182780 (Faslodex™): Development of a novel, "pure" antiestrogen
11. Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6
12. The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells
13. Steroidal pure antiestrogens
14. Gene regulation by steroid hormones
15. Nuclear receptor coactivators and corepressors
16. Molecular basis of agonism and antagonism in the oestrogen receptor
17. Human estrogen receptor transactivation capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
18. Identification of a third autonomous activation domain within the human estrogen receptor
19. Cloning of a novel estrogen receptor expressed in rat prostate and ovary
20. Use of pure antioestrogens to elucidate the mode of action of oestrogens
21. Action of "pure" antiestrogens in inhibiting estrogen receptor action
22. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
23. Antiestrogen ICI 164384 reduces cellular estrogen receptor content by increasing its turnover
24. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
25. Comparison between novel steroid-like and conventional nonsteroidal anti-oestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells
26. Activity of tamoxifen and new antiestrogen on estrogen receptor positive and negative breast cancer cells
27. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment
28. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164384 and ICI 182780 sensitive human breast cancer cell line, MCF-7/TAMR-1
29. Treatment with the pure antiestrogen faslodex (ICI 182780) induces tumor necrosis factor receptor 1 (TNFR1) expression in MCF-7 breast cancer cells
30. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
31. The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
32. Effects of 4-hydroxy-tamoxifen and a novel pure antiestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro
33. Pharmacokinetics, pharmacological and antitumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer
34. The effects of ICI 182780, a pure antioestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women
35. ICI 182780: A pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain
36. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
37. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer
38. A double-blind randomized trial comparing the efficacy and tolerability of Faslodex™ (fulvestrant) with Arimidex™ (anastrozole) in post-menopausal (PM) women with advanced breast cancer (ABC)
39. Comparison of efficacy and tolerability of fulvestrant (Faslodex™) with anastrozole (Arimidex™) in post-menopausal women with advanced breast cancer (ABC) - Preliminary results
40. A comparison of the single-dose pharmacokinetics (PK) of Faslodex™ (fulvestrant) 250 mg when given as either a one × 5-ml i.m. injection or two × 2.5-ml injections in postmenopausal (PM) women with advanced breast cancer (ABC)